Lyra Therapeutics, Inc. (LYRA) Stock Overview
Explore Lyra Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Lyra Therapeutics, Inc. (LYRA)
Key Financials
Key Financials
Market Cap
63K
P/E Ratio
-0.00
EPS (TTM)
$-6.89
ROE
12.11%
LYRA Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Lyra Therapeutics, Inc. (NASDAQ: LYRA) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Lyra Therapeutics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of LYRA on the NASDAQ shows an RSI of 17.14, suggesting the stock is in a an oversold condition. Our forecasting models predict a 12-month price target of $3.66 for the NASDAQ listing.
Key metrics behind Lyra Therapeutics, Inc.'s NASDAQ-traded stock include a P/E ratio of -0.00 and a market capitalization of 63K. Combined with our AI analysis, these give both institutional and retail investors a clear view of LYRA on the NASDAQ.